
This information was provided by prnewswire
Send your Press Release here.
First of their kind, myrcene nanoparticles are central to a novel, time-released therapeutic for neuropathic pain
LAS VEGAS, Nov. 20, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the treatment of neuropathic pain.
“We have achieved a significant research milestone in the creation of the myrcene-containing nanoparticles that are at the core of our patent-pending, myrcene-based complex mixtures for the treatment of neuropathic pain,” said Dr. Andrea Small-Howard. “Our colleagues at the Universidad de Sevilla had to overcome serious physical and chemical challenges to stabilize the very small myrcene molecules that are prone to evaporating. USE is also creating nanoparticle versions of the other compounds in our myrcene-containing complex mixtures; however, these other terpenoids and cannabinoids should not be as challenging because they are bigger, and USE has discovered ways to stabilize small molecules, like myrcene.”
Back in October of 2017, GB Sciences, Inc. entered into a Contract Research Agreement with the Universidad de Sevilla to develop a time-released version of GB Sciences’ proprietary, THC-free, myrcene-based chronic pain formulations, which contain a mixture of terpenoids and cannabinoids. USE researchers have created a prototype of the myrcene-containing nanoparticles, and GB and USE will begin functional testing of these formulations.
“We are so pleased to be working with GB Sciences on this very important project that has such potential to help people with neuropathic pain,” said Dr. Mercedes Fernández Arévalo (I+DNanomed, Website: grupos.us.es/idnanomed/). “Our research group has been diligently working on the development of new oral drug delivery systems to enhance the bioavailability of lipophilic molecules such as cannabinoids, and now, terpenoids.” Dr. Lucía Martín Banderas, I+DNanomed nanotech researcher at USE, said, “We believe that this may be the first terpenoid-nanoparticle ever created.”
John Poss, CEO and Chairman of GB Sciences, says: “We are proud to be collaborating with world-class nanotechnology researchers at the University of Seville. Together, we will work to bring a new class of cannabis-based medicines through developmental processes, including clinical trials registered with the US FDA, to bring much needed options for the treatment of neuropathic pain.“
Leave a Reply